Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies

BRUNETTA Paul G., SLIWKOWSKI MARK X
2004
OA: closed Metadata only
⚙ AI-generated summary by qwen3.7-flash, 2026-09-25 ⓘ

The application describes treating non-malignant indications, including endometriosis, with anti-ErbB2 antibodies such as rhuMAb 2C4.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The present application describes treatment of non-malignant indications, such as psoriasis, endometriosis, scleroderma, vascular diseases or disorders, respiratory disease, colon polyps or fibroadenoma, with anti-ErbB2 antibodies (e.g. rhuMAb 2C4).

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00